Date stringdate 2012-01-01 00:00:00 2023-12-31 00:00:00 | Stock_symbol stringlengths 1 5 | Article_title stringlengths 1 255 | Article stringlengths 1 342k |
|---|---|---|---|
2022-01-29 00:00:00+00:00 | ABBV | Can AbbVie Beat Pfizer in the Atopic Dermatitis Market? | Both AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) recently picked up regulatory approvals for JAK inhibitors for treating atopic dermatitis. In this Motley Fool Live video recorded on Jan. 19, Motley Fool contributors Keith Speights and Brian Orelli discuss whether AbbVie is likely to beat Pfizer in this large market.
10... |
2022-01-28 00:00:00+00:00 | ABBV | Value, Growth, or Momentum: What Kind of Investor are You? | The Covid-19 pandemic impacted all of us in many different ways. From work to family to finances, we were forced to adapt to a “new normal” that included staying home, jumping on Zoom calls, doing puzzles, and baking a ton of sourdough bread (or was that just me?).
The coronavirus crisis also likely changed how you inv... |
2022-01-28 00:00:00+00:00 | ABBV | Is a Beat Likely for AbbVie (ABBV) This Earnings Season? | AbbVie ABBV, slated to report fourth-quarter 2021 results on Feb 2, before market open, is expected to beat expectations. In the last reported quarter, the company delivered an earnings surprise of 3.10%.
AbbVie’s stock has gained 33.4% in the past year compared with an increase of 14.2% for the industry.
Image Source:... |
2022-01-28 00:00:00+00:00 | ABBV | Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards? | Biotech major Gilead Sciences Inc. GILD is slated to report fourth-quarter 2021 results on Feb 1, after market close.
The company has an excellent track record, with earnings beating estimates in all of the last four quarters, the average beat being 15.7%. In the last reported quarter, the company beat expectations by ... |
2022-01-27 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights: AbbVie, Edwards Lifesciences and Johnson Controls International | For Immediate Release
Chicago, IL – January 27, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. ABBV, Edwards ... |
2022-01-27 00:00:00+00:00 | ABBV | 2 Stocks to Buy During Market Turbulence Before Earnings | The S&P 500 and the Nasdaq last week posted their worst performances since the pandemic began. The benchmark index is officially in correction territory (down 10% or more from its highs) and the tech-heavy Nasdaq is down around 16%.
Both indexes are currently trading beneath their 200-day moving averages for the first ... |
2022-01-27 00:00:00+00:00 | ABBV | 2 Dirt-Cheap Dividend Stocks to Buy and Hold Forever | Dividend stocks are worth serious consideration, especially given the current state of the economy. With inflation near 40-year highs in the U.S., dividends can be a source of supplemental income for those who need it. And since the rise in prices can eat into investors' returns, opting for automatic dividend reinvestm... |
2022-01-27 00:00:00+00:00 | ABBV | Should Value Investors Pick AbbVie (ABBV) At Present? | Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking... |
2022-01-26 00:00:00+00:00 | ABBV | Top Analyst Reports for AbbVie, Edwards Lifesciences & Johnson Controls | Wednesday, January 26, 2022
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc. ABBV, Edwards Lifesciences Corp. EW, and Johnson Controls International plc JCI. These research reports have been han... |
2022-01-26 00:00:00+00:00 | ABBV | AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2021. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock p... |
2022-01-26 00:00:00+00:00 | ABBV | 2 Reasons to Buy AbbVie Stock, and 1 Reason to Sell | With 2021 net revenue estimated at $56.2 billion, AbbVie (NYSE: ABBV) is one of the world's most successful pharmaceutical companies. And given its massive pipeline of late-stage, drug-development programs in immunology, oncology, and aesthetics, the company likely has the opportunity to keep growing at a steady pace f... |
2022-01-26 00:00:00+00:00 | ABBV | 2 Stocks to Buy No Matter What Happens in 2022 | The U.S. equity market has been quite volatile in January 2022. Rising omicron cases, sticky inflation, which is expected to result in rate hikes, and now weaker-than-anticipated earnings results for tech stocks have negatively affected investor sentiment. Against this backdrop, CNBC's Jim Cramer expects the S&P 500 to... |
2022-01-25 00:00:00+00:00 | ABBV | Noteworthy Tuesday Option Activity: ABBV, AMED, REKR | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 32,524 contracts have traded so far, representing approximately 3.3 million underlying shares. That amounts to about 44.1% of ABBV's average daily trading volume over ... |
2022-01-25 00:00:00+00:00 | ABBV | J&J (JNJ) Q4 Earnings Beat Estimates by a Penny, Sales Miss | Johnson & Johnson’s JNJ fourth-quarter 2021 earnings came in at $2.13 per share, which beat the Zacks Consensus Estimate of $2.12 by a penny. Earnings increased 14.5% from the year-ago period.
Adjusted earnings exclude intangible amortization and some other special items. Including these items, J&J reported fourth-quar... |
2022-01-25 00:00:00+00:00 | ABBV | Johnson & Johnson (JNJ) Surpasses Q4 Earnings Estimates | Johnson & Johnson (JNJ) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $2.12 per share. This compares to earnings of $1.86 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 0.47%. A quarter ago... |
2022-01-24 00:00:00+00:00 | ABBV | AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis | AbbVie, Inc. ABBV announced that the FDA approved a second indication for its inflammatory drug, Skyrizi (risankizumab), to treat patients with active psoriatic arthritis.
Please note that Skyrizi was first approved to treat moderate-to-severe plaque psoriasis in 2019. Active psoriatic arthritis is the second FDA-appro... |
2022-01-24 00:00:00+00:00 | ABBV | AbbVie (ABBV) Gains But Lags Market: What You Should Know | AbbVie (ABBV) closed the most recent trading day at $132.16, moving +0.14% from the previous trading session. This change lagged the S&P 500's 0.28% gain on the day. At the same time, the Dow added 0.29%, and the tech-heavy Nasdaq gained 0.19%.
Coming into today, shares of the drugmaker had lost 0.83% in the past month... |
2022-01-24 00:00:00+00:00 | ABBV | These High-Yield Dividend Stocks Are Growing at Blazing Speeds | Are you looking for the best of both worlds from your stock picks? That is to say, do you want strong dividend yields as well as growth? Such names are few and far between. In many cases, you get one or the other.
There are some stocks, however, that offer above-average dividend payouts as well as above-average growth ... |
2022-01-24 00:00:00+00:00 | ABBV | 3 No-Brainer Healthcare Stocks to Buy Right Now for Less than $150 | Over the past few months, the stock market has been experiencing sell-offs which has created great buying opportunities for wise investors. There's nothing like getting a high-quality long-term investment at bargain prices. Shares of AbbVie (NYSE: ABBV), Merck (NYSE: MRK), and CVS Health (NYSE: CVS) all are below $150.... |
2022-01-23 00:00:00+00:00 | ABBV | Is AbbVie Stock a Top Pick for 2022? | Inflation is rampant. Treasury yields are rising, and the Federal Reserve is expected to raise interest rates multiple times in 2022. Many growth and technology stocks are getting hammered as a result, and investors are looking for a safe haven. In the case of AbbVie (NYSE: ABBV), look no further.
AbbVie is a global pr... |
2022-01-22 00:00:00+00:00 | ABBV | 1 Top Dividend Stock to Buy Right Now | Whether you're an experienced investor or brand new to investing, dividend stocks can provide an excellent means of increasing your portfolio returns while generating consistent capital to save or reinvest into your portfolio.
In this segment of Backstage Pass recorded on Jan. 5, Motley Fool contributor Rachel Warren d... |
2022-01-22 00:00:00+00:00 | ABBV | 3 Clinical Trials to Watch in the First Half of 2022 | Quite a few biopharmaceutical companies expect to report key clinical data in the coming months. In this Motley Fool Live video recorded on Jan. 12, 2022, Fool contributors Keith Speights and Brian Orelli discuss three clinical trials especially worth watching in the first half of 2022.
10 stocks we like better than Ar... |
2022-01-22 00:00:00+00:00 | ABBV | 2 Healthcare Stocks You Can Buy and Hold for the Next Decade | Investors have been stuck on a roller coaster of volatility in the overall market for nearly two months, leading some to eye dividend stocks to cushion the fall. But Abbott Laboratories (NYSE: ABT) and UnitedHealth Group (NYSE: UNH) give investors more than that one reason to be comfortable with an investment in these ... |
2022-01-21 00:00:00+00:00 | ABBV | Pharma Stock Roundup: GSK's Consumer Unit Offer Rejection, FDA Updates for AZN, PFE | This week, Glaxo GSK rejected a $68 billion buyout offer for its consumer healthcare business from consumer giant, Unilever. The FDA approved Pfizer PFE & AbbVie’s ABBV JAK inhibitor drugs to treat eczema and also granted priority review to AstraZeneca AZN and partner, Daiichi Sankyo’s supplemental biologics license ap... |
2022-01-21 00:00:00+00:00 | ABBV | J&J (JNJ) to Set the Stage for Pharma Sector Q4 Earnings | Johnson & Johnson JNJ will report fourth-quarter and full-year 2021 results on Jan 25, before market open. In the last-reported quarter, the company delivered an earnings surprise of 9.7%.
The healthcare bellwether’s performance has been pretty impressive, with the company exceeding earnings expectations in each of the... |
2022-01-20 00:00:00+00:00 | ABBV | 3 Value Stocks Breaking out in 2022 | (0:30) - Recap of Last Weeks Episode
(5:45) - Finding Value Stocks With Room To Run: Growth and Value
(15:35) - Tracey’s Top Stock Picks
(26:00) - Episode Roundup: CMA, CROX, ABBV, ANDE, INGR,
Podcast@Zacks.com
Welcome to Episode #265 of the Value Investor Podcast.
Every week, Tracey Ryniec, the editor... |
2022-01-20 00:00:00+00:00 | ABBV | Top Biotech Stocks To Buy Now? 5 For Your Late January Watchlist | Here Are 5 Biotech Stocks To Check Out In The Stock Market Today
As we move into the rest of 2022, it seems that biotech stocks could continue to be a viable play in the stock market. This can be attributed to the ongoing coronavirus concerns fueling the booming industry. Now, as the Omicron variant sweeps the globe, i... |
2022-01-20 00:00:00+00:00 | ABBV | 3 Dividend Aristocrats Yielding Over 4% | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
When it comes to income investing, we prefer dividend stocks that have demonstrated long histories of being able to raise their dividends throughout all kinds of economic conditions. There are many ways to find stocks with great dividend longevity, but one ... |
2022-01-19 00:00:00+00:00 | ABBV | See Which Of The Latest 13F Filers Holds AbbVie | At Holdings Channel, we have reviewed the latest batch of the 22 most recent 13F filings for the 12/31/2021 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 16 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed... |
2022-01-19 00:00:00+00:00 | ABBV | 3 Healthcare Stocks Ignoring the Market Mayhem | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Traders returned from the holiday-lengthened weekend to a wave of selling. Small-caps and growth stocks remain the hardest hit, but just about everything got tossed out on Tuesday. The mayhem sent the Russell 2000 index over 3% and the Nasdaq down 2.5%. In ... |
2022-01-19 00:00:00+00:00 | ABBV | 2 Best Warren Buffett Dividend Stocks to Buy Now | Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) CEO Warren Buffett is widely considered as one of the greatest investors of all time. One of Buffett's keys to success -- and a core lesson learned from his mentor Benjamin Graham -- has been to invest with a so-called "margin of safety." This concept centers on the idea o... |
2022-01-19 00:00:00+00:00 | ABBV | 3 Under-the-Radar COVID Stocks | COVID-19 has created a lot of volatility in the stock market. The whole market crashed in 2020, but many stocks quickly recovered. Indeed, there have been some high-flying pharmaceutical stocks that have skyrocketed as the biotech industry has fought back against the virus. And there are also some really interesting he... |
2022-01-19 00:00:00+00:00 | ABBV | 3 Dividend Stocks to Buy and Hold Forever | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Dividends are an important factor for many investors. The quarterly and annual payouts to shareholders can have a big impact on a portfolio’s growth over time. Dividend stocks can also serve as an income stream to people in retirement.
For this reason, many... |
2022-01-18 00:00:00+00:00 | ABBV | 7 of the Top-Rated Pharmaceutical Stocks for Q1 | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Pharmaceutical stocks haven’t really had much since the pandemic hit. Most of the talk has been about the companies in a race for vaccines or treatments and the companies that are distributing vaccines and treatments.
That hasn’t left a lot of space for oth... |
2022-01-18 00:00:00+00:00 | ABBV | Noteworthy ETF Inflows: VYM, VZ, ABBV, KO | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $1.2 billion dollar inflow -- that's a 2.8% increase week over week in outstanding units (from 370,014,28... |
2022-01-18 00:00:00+00:00 | ABBV | Zacks Industry Outlook Highlights: Roche, Pfizer, AbbVie and Merck | For Immediate Release
Chicago, IL – January 18, 2022 – Today, Zacks Equity Research discusses Roche RHHBY, Pfizer PFE, AbbVie ABBV and Merck MRK.
Industry: Big Pharma
Link:https://www.zacks.com/commentary/1851984/3-medical-services-stocks-to-buy-despite-near-term-industry-woes
The drug and biotech sectors remained in t... |
2022-01-17 00:00:00+00:00 | ABBV | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | AbbVie (ABBV) closed at $135.87 in the latest trading session, marking a +1.76% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.08%. Meanwhile, the Dow lost 0.56%, and the Nasdaq, a tech-heavy index, lost 4.81%.
Prior to today's trading, shares of the drugmaker had gained 4.89% over the past m... |
2022-01-17 00:00:00+00:00 | ABBV | AbbVie's (ABBV) Rinvoq Gets FDA Nod for Atopic Dermatitis | AbbVie Inc. ABBV announced that the FDA has approved its promising JAK inhibitor, Rinvoq (upadacitinib), for a new indication. The drug is now approved for the treatment of moderate to severe atopic dermatitis (“AD”) in adults and children aged 12 years and above whose disease did not respond to previous treatment and ... |
2022-01-17 00:00:00+00:00 | ABBV | Pfizer's (PFE) Cibinqo Gets FDA Nod for Atopic Dermatitis | Pfizer Inc. PFE announced that the FDA has approved its oral, once-daily, JAK1 inhibitor, Cibinqo (abrocitinib), for the treatment of refractory moderate-to-severe atopic dermatitis (AD) — also called eczema — in adult patients who did not respond to treatment with other drugs or when the use of other treatments is not... |
2022-01-17 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights: Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo | For Immediate Release
Chicago, IL – January 17, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer PFE, Beam Therapeut... |
2022-01-17 00:00:00+00:00 | ABBV | Is AbbVie a Good Dividend Stock to Buy Right Now? | If you're looking for better-than-average dividend yields, there's a pharmaceutical stock you need to take a look at. At recent prices, AbbVie (NYSE: ABBV) offers a 4.1% dividend yield that's impossible to ignore.
Over the past year, the average dividend-paying stock in the S&P 500 index delivered a lousy 1.3% yield. I... |
2022-01-16 00:00:00+00:00 | ABBV | Abbvie Inc Shares Near 52-Week High - Market Mover | Abbvie Inc (ABBV) shares closed today at 0.6% below its 52 week high of $136.73, giving the company a market cap of $240B. The stock is currently up 1.4% year-to-date, up 28.7% over the past 12 months, and up 175.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.... |
2022-01-16 00:00:00+00:00 | ABBV | 3 Pharma Stocks With Especially Juicy Dividends | Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.
We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NA... |
2022-01-14 00:00:00+00:00 | ABBV | U.S. FDA approves drugs from AbbVie, Pfizer to treat eczema | Recasts to include approval for Pfizer's drug
Jan 14 (Reuters) - The U.S. Food and Drug Administration approved drugs from AbbVie Inc ABBV.N and Pfizer Inc PFE.N for treating eczema, a skin disease, the companies said on Friday.
AbbVie's Rinvoq and Pfizer's Cibinqo have been approved to treat moderate-to-severe atopic ... |
2022-01-14 00:00:00+00:00 | ABBV | FDA approves expanded use of AbbVie's arthritis drug to treat eczema | Jan 14 (Reuters) - The U.S. Food and Drug Administration approved the expanded use of AbbVie Inc's ABBV.N arthritis drug to treat eczema, a skin disease, the company said on Friday.
The approval of Rinvoq for the treatment of moderate to severe atopic dermatitis, or eczema, was for patients 12 years and older who do no... |
2022-01-14 00:00:00+00:00 | ABBV | 5 Dividend Aristocrats Where Analysts See Capital Gains | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... |
2022-01-13 00:00:00+00:00 | ABBV | Pfizer's (PFE) Prevnar 20 Plus COVID Vaccine Study Succeeds | Pfizer PFE announced positive top-line data from a phase III study evaluating the co-administration of its newly approved 20-valent pneumococcal conjugate vaccine, Prevnar-20 with it and partner BioNTech’s BNTX mRNA-based COVID-19 vaccine at the same time in adults 65 years of age or older.
The study also evaluated the... |
2022-01-13 00:00:00+00:00 | ABBV | 4 Top Dividend Payers of the S&P 500 | While for some stocks in the S&P 500, it's their large dividend yields that make them attractive picks, I like to focus on companies with payout ratios below 50%. This shows a balance between fueling future business growth and returning cash to shareholders. Ultimately, these dividend growth stocks steadily outperform ... |
2022-01-12 00:00:00+00:00 | ABBV | Does Johnson & Johnson's Split Make Sense? | Johnson & Johnson (NYSE: JNJ) has been in business for well over a century. Many were blindsided when the company announced late last year that it would be splitting its medical device and pharmaceutical businesses from its consumer health business. The split is set to close sometime in the next two years. In this segm... |
2022-01-12 00:00:00+00:00 | ABBV | Notable Wednesday Option Activity: EOG, EBIX, ABBV | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in EOG Resources, Inc. (Symbol: EOG), where a total of 132,488 contracts have traded so far, representing approximately 13.2 million underlying shares. That amounts to about 329.5% of EOG's average daily trading vo... |
2022-01-12 00:00:00+00:00 | ABBV | 2 Monster Stocks to Buy for 2022 That Are Practically Minting Money | Since March 2009, growth stocks have enjoyed a very strong rally mainly due to the easy availability of cheap capital, thanks to an extremely low-interest rate environment. However, many growth stocks seem to have lost their sheen in the last few months of 2021 and early 2022. Stickier-than-expected inflation, a resurg... |
2022-01-12 00:00:00+00:00 | ABBV | Here's A Better Pharmaceutical Pick Over Merck Stock | We think that Bristol Myers Squibb stock (NYSE: BMY) currently is a better pick compared to its industry peer, Merck stock (NYSE: MRK), given its better growth prospects and comparatively lower valuation, with its stock trading at 3.0x trailing revenues, compared to 3.6x for MRK stock. That said, this gap in valuation ... |
2022-01-11 00:00:00+00:00 | ABBV | AbbVie To Present At J.P. Morgan Healthcare Conference; Webcast At 3:45 PM ET | (RTTNews) - AbbVie (ABBV) will participate in the 40th Annual J.P. Morgan Healthcare Conference.
The event is scheduled to begin at 3:45 PM ET on January 11, 2022.
To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events
The views and opinions expressed herein are the ... |
2022-01-11 00:00:00+00:00 | ABBV | AbbVie Confirms Outlook Of Over $15 Bln In Combined Risk-Adj. Sales For Rinvoq, Skyrizi In 2025 | (RTTNews) - AbbVie (ABBV) confirmed prior revenue guidance of more than $15 billion in combined Rinvoq or upadacitinib and Skyrizi or risankizumab risk-adjusted sales in 2025.
AbbVie now expects 2025 risk-adjusted sales of greater than $7.5 billion for Rinvoq and greater than $7.5 billion for Skyrizi.
The new Rinvoq sa... |
2022-01-10 00:00:00+00:00 | ABBV | Noteworthy ETF Inflows: VLUE, MU, ABBV, C | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI USA Value Factor ETF (Symbol: VLUE) where we have detected an approximate $242.6 million dollar inflow -- that's a 1.5% increase week over week in outstanding units (from 146,95... |
2022-01-09 00:00:00+00:00 | ABBV | 3 No-Brainer Big Pharma Stocks to Buy in 2022 | Going big can sometimes pay off. That's especially the case when you invest in the stocks of top large drugmakers.
We asked three Motley Fool contributors to identify the big pharma stocks that they think are no-brainer picks to buy in 2022. Here's why they chose AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Vertex Phar... |
2022-01-08 00:00:00+00:00 | ABBV | Just Four Days Till AbbVie Inc. (NYSE:ABBV) Will Be Trading Ex-Dividend | AbbVie Inc. (NYSE:ABBV) stock is about to trade ex-dividend in four days. Typically, the ex-dividend date is one business day before the record date which is the date on which a company determines the shareholders eligible to receive a dividend. It is important to be aware of the ex-dividend date because any trade on t... |
2022-01-07 00:00:00+00:00 | ABBV | AbbVie Submits Applications For Upadacitinib In Non-Radiographic Axial Spondyloarthritis To FDA | (RTTNews) - AbbVie (ABBV) said Friday that it has submitted applications seeking approvals for upadacitinib (RINVOQ, 15 mg once daily) to the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective sig... |
2022-01-06 00:00:00+00:00 | ABBV | Abbvie Inc Shares Near 52-Week High - Market Mover | Abbvie Inc (ABBV) shares closed today at 1.7% below its 52 week high of $138.15, giving the company a market cap of $240B. The stock is currently up 0.3% year-to-date, up 33.7% over the past 12 months, and up 168.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.... |
2022-01-06 00:00:00+00:00 | ABBV | 4 EV Charging Stocks to Buy Ahead of Biden’s National Network | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
If you’ve been thinking about electric vehicle charging stocks, you’re not alone.
The electric vehicle space has been a hot one on Wall Street for a couple of years now. And now the White House is putting renewed emphasis on the sector with its recent infra... |
2022-01-05 00:00:00+00:00 | ABBV | July 15th Options Now Available For AbbVie (ABBV) | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the July 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 191 days until expiration the newly trading contracts represent a possible opportunity for sellers of put... |
2022-01-05 00:00:00+00:00 | ABBV | AbbVie Gets Breakthrough Therapy Designation for Lung Cancer Treatment | The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to biopharmaceutical company AbbVie, Inc.’s (ABBV) investigational telisotuzumab vedotin (Teliso-V) to treat patients suffering from advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small... |
2022-01-04 00:00:00+00:00 | ABBV | AbbVie: Teliso-V Gets Breakthrough Therapy Designation | (RTTNews) - AbbVie (ABBV) announced FDA granted Breakthrough Therapy Designation to investigational telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose di... |
2022-01-04 00:00:00+00:00 | ABBV | Abbvie Inc Shares Approach 52-Week High - Market Mover | Abbvie Inc (ABBV) shares closed today at 1.0% below its 52 week high of $136.83, giving the company a market cap of $239B. The stock is currently up 0.0% year-to-date, up 32.4% over the past 12 months, and up 173.0% over the past five years. This week, the Dow Jones Industrial Average rose 0.8%, and the S&P 500 rose 0.... |
2022-01-04 00:00:00+00:00 | ABBV | This Big Pharma Stock Is Enriching Shareholders With Its Dividend. But Is It a Buy? | Two signs that a company is focused on creating significant value for its shareholders are when the company boosts its dividend and when it repurchases its shares at attractive valuations.
Pharma stock Bristol Myers Squibb (NYSE: BMY) recently announced a 10.2% hike in its quarterly dividend to $0.54 per share. And if ... |
2022-01-03 00:00:00+00:00 | ABBV | My Top 5 Dividend Stocks to Buy for 2022 | A strong dividend portfolio can be a powerful wealth-building tool, delivering gains from rising share prices and passive income. Many stocks pay dividends, but I would argue that blue chip companies are the winning strategy for long-term investors. In other words, let high-quality stocks do all the heavy lifting for y... |
2022-01-03 00:00:00+00:00 | ABBV | What Does This Regulatory News Mean for Bristol Myers Squibb's Shareholders? | In late November, the U.S. Food and Drug Administration (FDA) announced that it accepted Bristol Myers Squibb's (NYSE: BMY) New Drug Application for deucravacitinib as a treatment for patients with moderate-to-severe psoriasis.
With the FDA targeting a decision on deucravacitinib in September 2022, let's dive into the ... |
2022-01-02 00:00:00+00:00 | ABBV | Could This FDA Approval Create a Blockbuster Drug for AbbVie? | On Dec. 14, the U.S. Food and Drug Administration (FDA) approved AbbVie's (NYSE: ABBV) Rinvoq as a treatment for adult patients with psoriatic arthritis who failed at least one other tumor necrosis factor (TNF) inhibitor. A new indication is always a positive sign for a drugmaker, especially one like AbbVie that is see... |
2022-01-02 00:00:00+00:00 | ABBV | 22 Top Dividend Stocks to Buy and Hold in 2022 | I don't know how the stock market will perform in the new year. Wall Street analysts don't know, either. Any predictions are really only guesses.
There's no guesswork required, though, to expect that many stocks will continue to pay solid dividends regardless of what happens with the overall market. These are the kinds... |
2021-12-31 00:00:00+00:00 | ABBV | AbbVie Reaches Analyst Target Price | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $135.54, changing hands for $135.93/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a... |
2021-12-30 00:00:00+00:00 | ABBV | Best Stocks for 2022: Why AbbVie Looks Like High Dividend Growth Stock | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Editor’s note: This column is part of InvestorPlace.com’s Best Stocks for 2021 contest. Bob Ciura’s pick for the contest is AbbVie Inc. (NYSE:ABBV) stock.
Source: InvestorPlace
The stock market has something to offer every investor. There are stocks with hi... |
2021-12-30 00:00:00+00:00 | ABBV | 5 Dividend Stocks To Watch In 2022 | Are These The Best Dividend Stocks To Buy In 2022?
Despite the recent volatility in the stock market, 2021 is ending the year with strong gains. The S&P 500 is up 29%, which is significantly higher than its historical average. With the rising threats of the Omicron variant and inflation fears, it’s not difficult to ima... |
2021-12-30 00:00:00+00:00 | ABBV | Teva fueled opioid addiction in New York, jury finds | By Brendan Pierson
NEW YORK, Dec 30 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA fueled opioid addiction in New York state, a jury found on Thursday, a setback for a company still facing thousands of other opioid-related lawsuits around the United States.
The verdict, which followed a nearly six-month New Yor... |
2021-12-30 00:00:00+00:00 | ABBV | Abbvie Inc Shares Near 52-Week High - Market Mover | Abbvie Inc (ABBV) shares closed today at 0.4% below its 52 week high of $135.87, giving the company a market cap of $239B. The stock is currently up 32.4% year-to-date, up 35.5% over the past 12 months, and up 171.5% over the past five years. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2... |
2021-12-30 00:00:00+00:00 | ABBV | Notable Thursday Option Activity: BIIB, ABBV, GPN | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 29,370 contracts have traded so far, representing approximately 2.9 million underlying shares. That amounts to about 191% of BIIB's average daily trading volume over the pa... |
2021-12-30 00:00:00+00:00 | ABBV | 3 Dividend Kings That Are Yielding More Than 3% | Dividend Kings are among the safest dividend growth stocks you can invest in. These are stocks of companies that have track records of increasing dividend payments for at least 50 years in a row. To break that streak would require something massive to happen, which is why it's generally a safe assumption that not only ... |
2021-12-30 00:00:00+00:00 | ABBV | AbbVie Is Much More than Humira | AbbVie (NYSE: ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company was spun off of Abbott Labs in 2013 with essentially one product to sell, Humira.
The company took the huge amounts of cash that was thrown off by Humira and invested more than $50 dollars into research and develop... |
2021-12-28 00:00:00+00:00 | ABBV | Abbvie Inc Shares Near 52-Week High - Market Mover | Abbvie Inc (ABBV) shares closed today at 0.1% below its 52 week high of $134.48, giving the company a market cap of $237B. The stock is currently up 31.5% year-to-date, up 36.4% over the past 12 months, and up 170.6% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4... |
2021-12-28 00:00:00+00:00 | ABBV | AbbVie: Valuation, Debt, and Declining Margins Remain Risks | AbbVie (ABBV) is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health, and gastroenterology. The company was founded on October 19, 2011, and is headquartered in North Chicago, IL.
Shares of AbbVie have gains of 25.9% in 2021 and have u... |
2021-12-28 00:00:00+00:00 | ABBV | What AbbVie's Recent Drug News Means for Shareholders | At the end of last month, AbbVie (NYSE: ABBV) informed shareholders that it had submitted its application for Skyrizi to the European Medicines Agency (EMA) to treat patients aged 16 and older diagnosed with moderate to severe Crohn's disease.
But if Crohn's is approved as a third indication for the drug in the Europea... |
2021-12-27 00:00:00+00:00 | ABBV | 2 Top-Rated Biotech Stocks for 2022 | In 2021, the biotech sector remained in the spotlight. It played a critical role in putting the pandemic under control by developing COVID-19 vaccinations.
In addition, the sector's expansion in 2021 was aided by solid quarterly results, new product introductions, and regular M&A activity.
The pandemic, however, is far... |
2021-12-26 00:00:00+00:00 | ABBV | 3 Dividend Stocks to Buy If the Market Crashes in 2022 | Market crashes happen, and they tend to drag down the best stocks along with the rest of the market. It's impossible to predict the timing and severity of the next downturn, but it's easy to imagine one occurring in the near term.
The omicron variant keeps threatening to pinch the global economy. If the latest variant ... |
2021-12-25 00:00:00+00:00 | ABBV | Abbvie Inc Shares Close in on 52-Week High - Market Mover | Abbvie Inc (ABBV) shares closed today at 0.5% below its 52 week high of $133.77, giving the company a market cap of $235B. The stock is currently up 30.2% year-to-date, up 35.1% over the past 12 months, and up 168.6% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2... |
2021-12-24 00:00:00+00:00 | ABBV | Abbvie Inc Shares Approach 52-Week High - Market Mover | Abbvie Inc (ABBV) shares closed today at 0.5% below its 52 week high of $133.77, giving the company a market cap of $235B. The stock is currently up 30.2% year-to-date, up 35.0% over the past 12 months, and up 168.6% over the past five years. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 1... |
2021-12-24 00:00:00+00:00 | ABBV | 3 Best Buffett Stocks to Buy for the Long Haul | Since Warren Buffett took full control of Berkshire Hathaway in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of writing.
The Oracle of Omaha's reputation of buying the highest quality businesses means that many individual investors ... |
2021-12-23 00:00:00+00:00 | ABBV | Interesting ABBV Put And Call Options For February 2022 | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the February 2022 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new February 2022 contracts and identified one put and one call contract of particular interest.
The put... |
2021-12-23 00:00:00+00:00 | ABBV | iShares Core S&P Total U.S. Stock Market ETF Experiences Big Inflow | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $295.6 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (... |
2021-12-23 00:00:00+00:00 | ABBV | Abbvie Inc Shares Approach 52-Week High - Market Mover | Abbvie Inc (ABBV) shares closed today at 0.9% below its 52 week high of $133.28, giving the company a market cap of $229B. The stock is currently up 27.1% year-to-date, up 31.3% over the past 12 months, and up 166.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0... |
2021-12-22 00:00:00+00:00 | ABBV | Noteworthy Wednesday Option Activity: CF, CAMP, ABBV | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in CF Industries Holdings Inc (Symbol: CF), where a total of 14,266 contracts have traded so far, representing approximately 1.4 million underlying shares. That amounts to about 51.5% of CF's average daily trading ... |
2021-12-22 00:00:00+00:00 | ABBV | 3 of the Best Biotech Stocks for 2022 to Buy Now | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The coronavirus is kicking back into gear again, with investors licking their lips over biotech stocks. The omicron variant has roiled the world, which makes biotech’s the most pertinent investment option at this time.
Naturally, most of the market-leading ... |
2021-12-22 00:00:00+00:00 | ABBV | Got $1,000? These 3 Stocks Are Still Absurdly Cheap | Let's face it: Many stocks are ridiculously expensive. Even after the recent pullback, the S&P 500 index remains only 3% or so below its all-time high. The Shiller cyclically adjusted price-to-earnings (CAPE) ratio for the index is at its highest level since 2000.
But some stocks are definite outliers. If you've got $1... |
2021-12-21 00:00:00+00:00 | ABBV | Why CytomX Therapeutics Stock Is Crashing Today | What happened
Shares of CytomX Therapeutics (NASDAQ: CTMX) were crashing 40.1% lower as of 11:44 a.m. ET on Tuesday. The steep decline came after the company announced disappointing preliminary results from a phase 2 study evaluating CX-2029 in treating patients with either advanced squamous non-small cell lung cancer ... |
2021-12-21 00:00:00+00:00 | ABBV | Better Buy: Viatris vs. AbbVie | With a market cap of nearly $16 billion, the generic drugmaker Viatris (NASDAQ: VTRS) is minuscule in comparison to the profitable pharma titan AbbVie's (NYSE: ABBV) $228 billion. But, with Viatris' revenue growth starting to take off just as AbbVie's is decelerating, the fact that the smaller company is currently unpr... |
2021-12-18 00:00:00+00:00 | ABBV | 3 Reasons Why This Healthcare Stock Is a Long-Term Buy | If you think about it, discovering new treatments in healthcare can be similar to building a sound investment portfolio. A great deal of time is spent on research and monitoring, finding the right mix, and then waiting for that magical day. For pharmaceutical companies, that day might come when a product is approved or... |
2021-12-18 00:00:00+00:00 | ABBV | What to Make of the FDA's Latest Warning to AbbVie and Pfizer | The U.S. Food and Drug Administration (FDA) has placed additional warnings on the labels for JAK inhibitors marketed by AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). In this Motley Fool Live video recorded on Dec. 8, 2021, Motley Fool contributors Keith Speights and Brian Orelli talk about what to make of the FDA's lates... |
2021-12-16 00:00:00+00:00 | ABBV | 5 Biotech Stocks For Your Late December 2021 Watchlist | 5 Biotech Stocks To Check Out Before The End Of 2021
With the coronavirus pandemic kicking back into full swing, biotech stocks are once again at the forefront. For one thing, this part of thestock market todayhas and continues to work towards dealing with the pandemic. Now, as the Omicron variant sweeps the globe, I c... |
2021-12-16 00:00:00+00:00 | ABBV | Unstoppable Dividend King for 2022: AbbVie or Johnson & Johnson? | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) have plenty of similarities. They're both large-cap stocks in the healthcare space that are also Dividend Kings. Both appear to be undervalued based on their current and expected future earnings. They're the type of steady, long-term investments that retirees and ot... |
2021-12-15 00:00:00+00:00 | ABBV | Noteworthy ETF Inflows: DLN, ABBV, MRK, KO | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the WisdomTree U.S. LargeCap Dividend Fund (Symbol: DLN) where we have detected an approximate $334.7 million dollar inflow -- that's a 10.2% increase week over week in outstanding units (from 2... |
2021-12-15 00:00:00+00:00 | ABBV | 5 Top Healthcare Dividend Stocks To Watch Today | Check Out These Healthcare Dividend Stocks In The Stock Market Today
Inflation is becoming the hot new word when it comes to the stock market. Now, like it or not, it seems like inflation will be with us for a while. Sure, you could join the crowd and park your money in Apple (NASDAQ: AAPL). After all, Apple is deemed ... |
2021-12-14 00:00:00+00:00 | ABBV | FDA Approves AbbVie's RINVOQ To Treat Active Psoriatic Arthritis | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration has approved RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers.
The FDA approval is supported by d... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.